Renamed Coave Therapeutics Raises $39m To Fund Its Next-Gen Gene Therapies
Conjugation Tech Could Improve Gene Delivery
Executive Summary
The company aims to overcome drawbacks of existing gene therapy platforms, starting in ocular and CNS diseases.
You may also be interested in...
GenSight CEO Sees Bright Future After Therapy Gave Blind Man Partial Sight
French biotech GenSight will prioritize its optogenetic GS030 treatment after the combination showed breakthrough results in a form of blindness, its CEO tells Scrip.
After Years Of Setbacks, Marinus Closes In On Rare Epilepsy Opportunity
After multiple failed attempts to treat rare conditions, Marinus is on the cusp of success with ganaxolone in genetic epilepsy, and has secured a new European partner in Orion.
Back To The Day Job? AstraZeneca’s Pangalos Looks Ahead To A Post-Pandemic Pipeline
Has AstraZeneca been able to maintain its R&D productivity, even during a pandemic, and with the huge task of delivering a not-for-profit COVID-19 vaccine to the world?AstraZeneca’s Mene Pangalos believes the company has not missed a beat, and can find new energy from finally working together in its new R&D headquarters.